Condition
Crohn's disease news across medications, symptoms, tests, procedures, complications, research, access, and daily life.
Page 3 of 53 · 2510 articles
Cure8 found this source from youtube.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.
Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from firstwordpharma.com.
Positive Phase 3 pediatric data could expand access to Omvoh for children with ulcerative colitis and change treatment options. That matters to families, clinicians, and patients using or considering biologic therapy.
Early antibody signatures could allow earlier identification of people at higher risk for Crohn’s disease or ulcerative colitis, which might eventually enable closer monitoring or preventative research.
Narrowing (stenosis) can cause obstructive symptoms and often leads to surgery; evidence that a biologic—guselkumab—may improve non-passable stenosis and reduce fibrosis-associated biology could affect treatment planning...
Early Phase 2a data suggest a dual-target IBD therapy (ABBV-466) produced higher endoscopic remission than single-pathway agents, which could matter if later trials confirm better outcomes for people with...
Cure8 found this source from pluang.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.
This mid-stage trial suggests a dual-targeting combo may improve endoscopic remission rates in Crohn’s disease compared with IL-23 inhibition alone, which could influence future treatment options and company strategies...
Perianal fistulas are a common, debilitating complication of Crohn’s disease; longer-term data on treatments that can produce durable fistula remission are directly relevant to patients and clinicians managing this...
Overlap of EoE and IBD appears uncommon but more frequent than in the general population and is linked to more allergic disease and higher steroid exposure without clearer increases in esophageal scarring. That may...
This study suggests coconut oil and its myristic acid component reduced Crohn’s-like inflammation in a mouse model via effects on the microbiome and regulatory T cells, which could point toward new dietary or adjunctive...
This study tested a blood biomarker (zonulin) tied to gut barrier function and found no evidence of increased intestinal permeability in these Behçet syndrome patients, unlike in the Crohn’s disease group.
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Community and awareness. The original article is from msn.com.
Cure8 found this source from pluang.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications. Open the original article for the full details.
Patients with upper GI Crohn’s often have a more aggressive course; this registry analysis suggests they usually respond to biologic drugs similarly to other patients but still carry a higher long-term chance of needing...
If validated, antibody-based signals found years before symptoms could allow earlier risk identification and research into why immune responses precede IBD. That may matter for patients and clinicians interested in early...
Cure8 found this source from intellectia.ai, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
A pediatric label for Omvoh could make an additional biologic option available for children with moderate-to-severe ulcerative colitis who respond to treatment. Trial results reported one-year remission among responders,...
Cure8 could only read part of this source from endpoints.news, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical...
New Phase 2a data suggest a combination therapy (ABBV-466) produced higher endoscopic remission at Week 24 than either component alone — a potential sign that multi-target approaches might improve Crohn's outcomes.
Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.
Knowing which kids need biologics after EEN could help families and clinicians plan follow-up and monitoring. Simple blood tests like complement C4 and RDW may have predictive value, if confirmed.
PRO2 and PRO3 were recorded far more often than CDAI or HBI in routine care and correlated strongly with those clinician-scored indices, so they may be a practical way to monitor Crohn’s activity and support real-world...
People with Crohn's disease may be interested because the paper provides molecular hypotheses linking acupuncture to immune-related pathways (neutrophils, M2 macrophages) and nominates FER as a potential...
Perianal fistulas are a common, disabling complication of Crohn’s disease. A medication that provides durable fistula remission through 48 weeks could change treatment options for people with Crohn’s and perianal...
These Phase 3 results suggest guselkumab (TREMFYA) may provide durable clinical and endoscopic benefit through three years for adults with moderate to severe Crohn’s disease and may help with perianal fistula...
Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.
Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical...
A combo that adds an α4β7 blocker to an IL-23 inhibitor showed higher endoscopic remission at Week 12 than either drug alone in a phase 2 Crohn’s trial, which could point to a new treatment strategy for people who’ve...
Mid-stage data suggest a dual-targeting approach may improve endoscopic remission for people with moderate–severe Crohn's disease, including many who previously failed advanced therapies. If confirmed in larger trials,...
The report suggests a dual-targeting antibody combination (IL-23 p19 + α4β7) may achieve higher endoscopic remission than either mechanism alone in a treatment-experienced Crohn's population, which could matter for...
Personal stories can help people with IBD feel seen and show that fatigue and pain from Crohn’s disease don’t always prevent meaningful physical activity or community involvement. It also highlights fundraising and...
If validated, antibody signatures could enable earlier identification of people at higher risk of developing IBD and help predict which patients may develop more severe disease, creating opportunities for earlier...
If validated, antibody-based signatures could enable much earlier detection of IBD and help identify people at risk of more severe Crohn’s disease years before symptoms—potentially opening opportunities for research on...
If validated, blood antibody patterns could allow earlier identification of people at risk for Crohn’s disease or ulcerative colitis — potentially before bowel damage occurs — opening opportunities for earlier monitoring...
Crohn’s disease can rarely affect the nose and nasopharynx. Recognizing this can shorten diagnostic delay and lead to appropriate immunosuppressive or biologic treatment that may prevent complications.
A simple, low-cost fecal blood assay for mice can speed and lower the cost of preclinical studies of colorectal cancer and GI diseases. For IBD/Crohn’s research, it offers a way to monitor intestinal bleeding and link it...
The study suggests people with IBD consumed more dietary emulsifiers than healthy controls and found initial links between higher UPF/emulsifier intake and worse IBD-related events, which could be important if diet...
Children with IBD can present differently than adults and may show early signs outside the gut. The special-issue papers highlight improved, less-invasive diagnostic tools and increasing use of targeted biologic...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Upadacitinib. The original article is from moomoo.com.
Fibrostenotic strictures are a major unmet need in Crohn’s disease because anti-inflammatory drugs often cannot reverse established scarring; IL-11 is a biologically plausible target that might selectively affect...
Fatigue is a common, disabling issue in Crohn’s disease with unclear biology. This study suggests measurable brain-structure differences correlate with fatigue severity and may modify how disease activity influences...
The article discusses peptide compounds that people with Crohn’s and other IBDs are exploring for gut barrier support and inflammation — a topic many patients consider when seeking adjunctive or experimental approaches.
IUS with the IBUS‑SAS score may offer a reliable, noninvasive way to monitor Crohn’s disease activity that correlates with clinical scores and biomarkers and aligns well with CT/MRI for most findings.
Peptides are being studied for targeted ways to reduce gut inflammation and help restore the intestinal lining — potential relevance for future Crohn’s/IBD therapies.
People with Crohn’s or IBD often try nutritional supplements; this article surveys claims and early research about collagen peptides that some hope could support gut lining and reduce inflammation. It’s useful for...
Longer-term and real-world data help patients and clinicians understand how well risankizumab and upadacitinib maintain clinical and endoscopic improvement over years of treatment, and early data on an investigational...
MRE is a widely used, noninvasive test that increasingly helps characterize disease phenotype and prognosis in Crohn's disease and IBD, which can affect monitoring and treatment planning.
